Objective: The Microcompetition with ForeignDNA theory, proposed by Hanan Polansky in 2003, describes how latent virusescan cause chronic conditions, including fatigue. The Gene-Eden-VIR formula wasdesigned to target latent viruses. Therefore, the theory predicts thattreatment with Gene-Eden-VIR will decrease fatigue in individuals infected witha latent virus. The objective of this study was to test this prediction.Framework: A post marketing clinical study that followed FDA guidelines.Treatment: Gene-Eden-VIR, a dietary supplement. A capsule of Gene-Eden-VIR includes 100 mg of quercetin,150 mg of green tea extract, 50 mg of cinnamon extract, 25 mg of licorice extract, and 100 mcg ofselenium. The treatment included 1, 2, 3, or 4 capsules per day, and lasted 2to 54 weeks. Population: 100 individuals infected with a latent virus,including the Human Papillomavirus HPV, Epstein Barr Virus EBV, HerpesSimplex Virus HSV, Human Cytomegalovirus HCMV, and Hepatitis C Virus HCV. Agesranged from 20 to 66. All participants reported a feeling of fatigue at thestart of the study. Specifically, 98, 90, and 79 participants reported a feeling of general, physical,and mental fatigue, respectively. Results: Following treatment with Gene-Eden-VIR, 73.47%, 62.22%,and 47.36% reported a decrease in their feeling of general, physical, andmental fatigue, respectively. The participants also reported a statisticallysignificant decrease in every aspect of fatigue tested in the study. Theresults also showed a duration effect, that is, those treated for 2 months ormore reported a larger decrease in their feeling of fatigue general, p 0.03, n 65; physical and mental, p 0.05, n 70. The results showed nointerviewer bias, and no selection bias. In addition, the results showedtherapeutic consistency under varying manufacturing conditions. Theparticipants reported no side effects after taking Gene-Eden-VIR. Conclusions: This post marketingclinical study showed that treatment with Gene-Eden-VIR safely decreased the feeling of general,physical, and mental fatigue in individuals infected with a latent virus. Since most individualsare infected with a latent virus, health care practitioners should recommend Gene-Eden-VIR as afirst line treatment for fatigue. The results of this post marketing clinicalstudy support the Microcompetition with Foreign DNA theory.